ReviewTrends in endocrinology and metabolism: TEM2012
Fibroblast growth factor 23: state of the field and future directions.
Review in Trends in endocrinology and metabolism: TEM, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 137 citations in OpenAlex.
- Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.Pflugers Archiv : European journal of physiology · 2018Trial
- Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Trial
- Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease.PloS one · 2013Trial
- Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Three-Phase Serum Concentration Kinetics of FGF23 in a Clinical Model of Acute Myocardial Infarction.Cells · 2026Article
- Marked regression of calcinosis with canakinumab in hyperphosphatemic familial tumoral calcinosis.JBMR plus · 2026Article
- Hearing impairment in X-linked hypophosphatemia: a review.JBMR plus · 2025Article
- Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission.bioRxiv : the preprint server for biology · 2025Article
- Orthopedic surgical treatment of osteomalacia induced by culprit soft tissue tumor in the hip region: a single-center retrospective study.BMC musculoskeletal disorders · 2025Article
- A Novel Pathogenic Variant in Fibroblast Growth Factor 23 outside the Furin-Recognizing RXXR Motif in an Autosomal Dominant Hypophosphatemic Rickets Patient.Hormone research in paediatrics · 2025Article
- Lipocalin 2-A bone-derived anorexigenic and β-cell promoting signal: From mice to humans.Journal of diabetes · 2024Review
- Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation.Blood · 2023Article
- Fam20c regulates the calpain proteolysis system through phosphorylating Calpasatatin to maintain cell homeostasis.Journal of translational medicine · 2023Article
- FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis.CNS neuroscience & therapeutics · 2023Review
- Between a rock and a hard place: Regulation of mineralization in the periodontium.Genesis (New York, N.Y. : 2000) · 2022Review
- Unusual Presentation and Surgical Treatment of a Phosphaturic Mesenchymal Tumor in a Knee.Frontiers in surgery · 2022Article
- Iron and 25-hydroxyvitamin D in postmenopausal women with osteoporosis.American journal of translational research · 2022Review
- A novelFrontiers in endocrinology · 2022Article
- Article
- Disentangling the relationship between bone turnover and glucose homeostasis: A prospective, population-based twin study.Bone reports · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that regulates and is regulated by blood levels of phosphate and active vitamin D. Post-translational glycosylation by the enzyme GALNT3 and subsequent processing by furin have been demonstrated to be a regulated process that plays a role in regulating FGF23 levels. In physiologic states, FGF23 signaling is mediated by an FGF receptor and the coreceptor, Klotho. Recent work identifying a role for iron/hypoxia pathways in FGF23 physiology and their implications are discussed. Beyond its importance in primary disorders of mineral metabolism, recent work implicates FGF23 in renal disease-associated morbidity, as well as possible roles in cardiovascular disease and skeletal fragility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.